萬達生物製藥 VNDA 深 滬
已收盤 12-19 16:00:00 美东时间
6.75
+0.080
+1.20%
華盛通- 最 高6.94
- 今 開6.71
- 成交量 148.41万股
- 最 低 6.69
- 昨 收 6.67
- 總市值 3.99亿
- 52周最高 7.05
- 市盈率 靜 --
- 換手率 2.51%
- 52周最低 3.8092
- 委 比 90.39%
- 總股本 5908.91万
- 歷史最高 33.44
- 量 比 0.88
- 振 幅 3.75%
- 歷史最低 2.92
- 每 手 1
- 風險率 0.49%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Vanda Pharmaceuticals Submitted An FDA Biologics License Application For Imsidolimab For Generalized Pustular Psoriasis
Vanda has requested priority review for the BLA, citing GPP's status as a rare orphan disease with significant unmet need. If granted, priority review would establish a six-month review cycle, with a potential FDA
12-15 20:14
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
WASHINGTON, Dec. 11, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the J.P. Morgan Healthcare Conference in San ...
12-12 06:02
Market-Moving News for December 5th
PRAX: 30% | Praxis Precision Medicines shares are trading higher after the company announced the completion of its pre-NDA meeting with the FDA and it gained alignment from the agency. The company announced results
12-05 20:24
FDA re-review of Vanda tradipitant partial clinical hold extended
The US FDA is extending by a matter of days a re-review of a partial clinical hold on long-term studies of Vanda Pharmaceuticals' (VNDA) tradipitant for motion sickness. The agency was supposed to com...
11-29 00:25
FDA Fast-Tracks Vanda's Motion Sickness Drug Review After Leadership Shake-Up
FDA accelerates re-review of Vanda's tradipitant and begins label talks, keeping its motion sickness drug on track for key 2025 decisions.
11-29 00:10
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
FDA requests, and Vanda agrees to, a brief extension (to December 5, 2025) for the expedited re-review of the partial clinical hold on long-term studies Separately, FDA recently issued label...
11-28 20:00
美股大行评级 | 高盛上调百度、美敦力、晶科能源等多只个股目标价；家得宝遭9家机构下调目标价；
今日重点评级关注：富国银行：维持Annexon"超配"评级，目标价从14美元升至27美元；瑞穗：上调Relmada Therapeutics评级至"跑赢大市"，目标价从1美元升至10美元
11-20 10:28
HC Wainwright & Co. Reiterates Buy on Vanda Pharmaceuticals, Maintains $20 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and maintains $20 price target.
11-19 19:52
美股牛股 | 嘉楠科技飙升20%，Q3挖矿收入激增241%；Diginex涨超19%，公司与EVIDENT达成战略合作
嘉楠科技飙升20%，Q3营收破1.5亿美元，挖矿收入激增241%；Diginex涨超19%，公司与EVIDENT达成战略合作>>
11-19 16:54
Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients
Vanda Pharmaceuticals' tradipitant successfully reduced Wegovy-induced vomiting by 50% in a clinical trial. Phase 3 anticipated in H1 2026.
11-18 23:49
